Skip to main content
Ying-Chih Chiang on Muck Rack

Ying-Chih Chiang

As seen in: Nature, MDPI, PNAS, The Journal of Biological Chemistry
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Ying-Chih

Contact Ying-Chih, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Discovery and substrate specificity engineering of nucleotide halogenases - Nature Communications

|
By Ying-Chih Chiang
| Nature Verified
Abstract C2′-halogenation has been recognized as an essential modification to enhance the drug-like properties of nucleotide analogs. The direct C2ʹ-halogenation of the nucleotide 2′-deoxyadenosine-5′-monophosphate (dAMP) has recently been achieved using the Fe(II)/α-ketoglutarate-dependent nucleotide halogenase AdaV. However, the limited substrate scope of this enzyme hampers its broader applications.
Open in Who Shared Issue with article?

Structural insights into the activation and inhibition of CXC chemokine receptor 3 - Nature Structural & Molecular Biology

|
By Xiankun Wang, Ying-Chih Chiang, Ruobing Ren
| Nature Verified
Abstract The chemotaxis of CD4+ type 1 helper cells and CD8+ cytotoxic lymphocytes, guided by interferon-inducible CXC chemokine 9–11 (CXCL9–11) and CXC chemokine receptor 3 (CXCR3), plays a critical role in type 1 immunity. Here we determined the structures of human CXCR3–DNGi complexes activated by chemokine CXCL11, peptidomimetic agonist PS372424 and biaryl-type agonist VUF11222, and the structure of inactive CXCR3 bound to noncompetitive antagonist SCH546738.
Open in Who Shared Issue with article?

StackTHPred: Identifying Tumor-Homing Peptides through GBDT-Based Feature Selection with Stacking Ensemble Architecture

|
By Jiahui Guan, Lantian Yao, Chia-Ru Chung, Ying-Chih Chiang
| MDPI
Abstract : One of the major challenges in cancer therapy lies in the limited targeting specificity exhibited by existing anti-cancer drugs. Tumor-homing peptides (THPs) have emerged as a promising solution to this issue, due to their capability to specifically bind to and accumulate in tumor tissues while minimally impacting healthy tissues.
Open in Who Shared Issue with article?
See all 7 articles